This conference, with the theme of "Building an Innovative Ecosystem for a Shared Industrial Future," focuses on the development trends in the pharmaceuticals industry, including biopharmaceuticals' expansion overseas and international innovation, investment and financing for innovative drugs, and medical devices. It aims to create an annual event that is "high-end, international, professional, and multi-dimensional."Prepayment Record for China-Based Biotech Overseas Expansion Refreshed.September 30, Regor Therapeutics（Regor Pharmaceuticals）Announced that it has reached an acquisition agreement with Genentech, a subsidiary of Roche, for the next-generation CDK inhibitor.According to the terms of the agreement, Regor Therapeutics will receive an upfront payment of $850 million and is eligible to receive additional cash payments based on the achievement of certain predefined development, regulatory, and commercial milestones. Genentech will be responsible for global clinical development, manufacturing, and commercialization. Regor Therapeutics will continue to manage the two ongoing Phase I clinical trials until completion.The transaction is expected to be completed in the fourth quarter of 2024.Regor Therapeutics is a company focused on developing innovative drugs to meet significant unmet needs in the fields of oncology, metabolism, and autoimmunity, leveraging its proprietary CARD platform.(Computer-Accelerated New Drug Development)The platform has advanced more than a dozen internally discovered assets to different stages of preclinical and clinical development.According to the Regor Therapeutics website, there are currently two CDK inhibitors in its pipeline: RGT-419B and QR-6401. RGT-419B is a CDK2/4/6 inhibitor, which is undergoing two Phase I clinical trials for HR+/HER2- breast cancer. QR-6401 is a CDK2 inhibitor currently in the preclinical stage.Regor Therapeutics Pipeline
Following last year's frequent interest from MNCs in locally produced products, this year’s "going global" trend has also reached new heights.Just a month ago, Merck and Tongrun Bio announced a collaboration regarding CN201, a CD3xCD19 bispecific antibody developed by Tongrun Bio. Merck will acquire global rights to CN201 through its subsidiary, while Tongrun Bio will receive $700 million in upfront cash payments and up to $600 million in milestone payments, bringing the total deal value to $1.3 billion.At that time, this deal became a hot topic in China's Biotech outbound transactions, with an upfront payment second only to that of Baili Tianheng's authorized BD.In December last year, SystImmune, a wholly-owned subsidiary of Baili Tianheng, reached a cooperation agreement with BMS regarding the EGFR×HER3 bispecific antibody ADC product BL-B01D1. BMS will pay SystImmune an upfront payment of 800 million US dollars, near-term contingent payments of up to 500 million US dollars, and potential milestones totaling 7.1 billion US dollars.The globalization of Chinese pharmaceutical companies is an important trend in the current pharmaceuticals industry. According to incomplete statistics, there have been over 20 outbound licensing deals by Chinese pharmaceutical companies this year alone. The success of globalization depends on whether Biotech can address unmet clinical needs and possesses the capability to advance clinical trials overseas. This includes the rationality of clinical development strategies as well as the ability to seize the right timing.There is no denying that the products of domestic Biotech companies are increasingly gaining recognition. And the moment the record was written, it was destined to be rewritten.
Welcome to follow the media matrix of Tongxiyi.↓↓↓
